ArriVent BioPharma Reports First Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: May 8, 2024
NEWTOWN SQUARE, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first quarter ended March 31, 2024, and highlighted recent Company progress.
Read more at globenewswire.com
